NERV
Minerva Neurosciences, Inc.Company Information
- Company Name
- Minerva Neurosciences, Inc.
- CIK
- CIK0001598646
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- NERV: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- NERV
SEC filing data through
Insider Sentiment
- Last purchase
- 2020-09-10
- Last sale
- 2023-05-02
- Shares purchased (TTM)
- 0
- Shares sold (TTM)
- 29,303
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 42,404,632
- Shares outstanding
- 46,599,044
- Ownership
- 91.00%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- 13.35%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series A Convertible Preferred Stock | -0 | 0 | 0 | - | - | - | - | - | - | - | - | - | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 25 | 33 | 82 | 12 | 15 | 17 | 21 | 27 | 31 | 35 | 41 | 47 | ||||||
| Marketable Securities Current | 51 | 45 | - | - | - | - | - | - | - | - | - | - | ||||||
| Restricted Cash Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Prepaid Expense Current | 4 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | ||||||
| Assets Current | 80 | 79 | 83 | 13 | 16 | 18 | 22 | 28 | 31 | 36 | 42 | 48 | ||||||
| Capitalized Computer Software Net | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Property Plant And Equipment Net | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Goodwill | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | ||||||
| Assets | 95 | 94 | 98 | 28 | 30 | 33 | 37 | 43 | 46 | 51 | 57 | 63 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 2 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | 1 | ||||||
| Accounts Payable And Other Accrued Liabilities Current | 3 | 2 | 2 | 2 | 2 | 1 | 1 | 4 | 3 | 1 | 2 | 2 | ||||||
| Liabilities Current | 4 | 4 | 2 | 3 | 3 | 2 | 3 | 4 | 4 | 3 | 3 | 3 | ||||||
| Liabilities | 297 | 343 | 234 | 63 | 63 | 62 | 63 | 64 | 91 | 87 | 85 | 83 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 583 | 560 | 548 | 371 | 370 | 370 | 370 | 369 | 369 | 369 | 368 | 368 | ||||||
| Retained Earnings Accumulated Deficit | -797 | -814 | -689 | -405 | -402 | -399 | -395 | -391 | -414 | -405 | -397 | -388 | ||||||
| Stockholders Equity | -213 | -254 | -141 | -35 | -32 | -29 | -26 | -22 | -44 | -37 | -28 | -20 | ||||||
| Liabilities And Stockholders Equity | 95 | 94 | 98 | 28 | 30 | 33 | 37 | 43 | 46 | 51 | 57 | 63 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 250 | 250 | 250 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | 125 | ||||||
| Common Stock Shares Issued | 47 | 44 | 43 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | ||||||
| Shares Outstanding | 47 | 44 | 43 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | 7 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMinerva Neurosciences, Inc. (NERV) — SEC Financial Statements & Analysis
Minerva Neurosciences, Inc. (NERV) is a pharmaceutical preparations company, incorporated in MA. Minerva Neurosciences, Inc. trades on Nasdaq as: NERV. Minerva Neurosciences, Inc. (NERV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, Minerva Neurosciences, Inc. carries a market cap of $258.62M, a P/E ratio of -0.66x, a P/B ratio of -1.21x, an enterprise value of $233.87M, and an EV/EBITDA multiple of -6.66x. On profitability, it posts a Return on Equity (ROE) of 321.38% and a Return on Assets (ROA) of -628.40%. Per share, it reports EPS of $-8.46, diluted EPS of $-4.99, free cash flow per share of $-0.56, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -3611.70% year-over-year and EPS growth of -670.40% year-over-year. On the balance sheet, it maintains a current ratio of 20.14x, a quick ratio of 19.04x, working capital of $75.77M, a debt-to-equity ratio of -1.39x, a debt ratio of 3.12, free cash flow of $-26.17M (TTM), and net debt of $-24.75M. Figures sourced from SEC EDGAR.
- Market Cap
- $258.62M
- P/E TTM
- -0.66x
- EPS TTM
- $-8.46
- P/B TTM
- -1.21x
- ROE TTM
- 321.38%
- ROA TTM
- -628.40%
- Debt To Equity
- -1.39x
- Free Cash Flow TTM
- $-26.17M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Minerva Neurosciences, Inc. in?
Minerva Neurosciences, Inc. (NERV) operates in the Pharmaceutical Preparations industry.
What exchange does NERV trade on?
Minerva Neurosciences, Inc. (NERV) trades on the Nasdaq.
Where is Minerva Neurosciences, Inc. incorporated?
Minerva Neurosciences, Inc. is incorporated in MA.
When was Minerva Neurosciences, Inc. (NERV)'s most recent SEC filing?
Minerva Neurosciences, Inc. (NERV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is NERV's market cap?
Minerva Neurosciences, Inc. (NERV) has a market capitalization of $258.62M as of 2026-06-30.
What is NERV's EPS (earnings per share)?
Minerva Neurosciences, Inc. (NERV)'s trailing twelve month EPS is $-8.46 as of 2026-06-30.
What is NERV's ROE (return on equity)?
Minerva Neurosciences, Inc. (NERV)'s trailing twelve month Return on Equity (ROE) is 321.38% as of 2026-06-30.
What is NERV's ROA (return on assets)?
Minerva Neurosciences, Inc. (NERV)'s trailing twelve month Return on Assets (ROA) is -628.40% as of 2026-06-30.
What is NERV's EV/EBITDA?
Minerva Neurosciences, Inc. (NERV)'s trailing twelve month EV/EBITDA is -6.66x as of 2026-06-30.